Pantoprazole Linked to Rare Lupus Skin Condition
A case report published in August 2026 highlights a drug-induced autoimmune reaction in a 73-year-old patient.
Updated on Oct. 14, 2026 in Arthritis
Live Poll
Do you trust that common heartburn medications are safe for long-term daily use?
Medical researchers documented a case of drug-induced subacute cutaneous lupus erythematosus (SCLE) in a 73-year-old woman in the Netherlands. The patient developed distinct ring-shaped skin lesions after using pantoprazole for 10 months.
Why it matters
Identifying specific triggers for autoimmune reactions is critical for patient management, as certain medications may inadvertently induce symptoms that mimic or exacerbate lupus. Doctors were able to resolve the patient's condition by removing the identified drug trigger and providing targeted treatment.
A skin biopsy confirmed inflammation and cellular damage at the base of the outer layer of skin. Blood tests for the patient revealed positive antinuclear antibodies and high levels of anti-Ro antibodies.
The players
Leiden University Medical Center
This is the Dutch medical institution where the researchers who documented the case are based.
Medicines and Healthcare products Regulatory Agency
This United Kingdom executive agency is responsible for ensuring that medicines and medical devices work and are acceptably safe.
The details
The medical team identified the rash by its polycyclic appearance on sun-exposed areas of the skin. Treatment involved discontinuing pantoprazole and administering a topical steroid alongside hydroxychloroquine, allowing the lesions to clear over four months.
Timeline
A 2014 study by Danish researchers analyzed 24 SCLE patients over 19 years.
The UK MHRA released a safety update regarding drug-induced SCLE in 2015.
The case report was published in August 2026.
The Big Picture
This case report follows the clinical framework established by the 2015 UK MHRA safety update on drug-induced SCLE. It provides a contemporary example that reinforces existing medical guidelines regarding the monitoring of autoimmune responses to common medications.
Patients who notice new or recurring rashes while taking acid-reducing medication should consult their physician to determine if a change in prescription is necessary. Medical professionals utilize these findings to better screen for potential drug-induced autoimmune reactions during long-term treatment.
The takeaway
Patients should remain vigilant regarding new dermatological symptoms when beginning or continuing long-term medication regimens. Consulting with a healthcare provider remains the essential step for identifying and mitigating potential drug-induced side effects.
Further reading
Learn more about the management of complex autoimmune conditions in our Arthritis section.
Live Poll
Do you trust that common heartburn medications are safe for long-term daily use?
